Paul S. Changelian, Ph.D. and Peter L. Toogood, Ph.D. have been appointed to Lycera Corp.’s drug development team. Dr. Changelian, previously director of inflammation biology at Pfizer, will serve as vice president of biology. Dr. Toogood, who was an associate director and research fellow at Parke-Davis and Pfizer, will be Lycera’s vice president of chemistry and chemical biology. Both will play important roles in Lycera’s efforts to develop novel small molecule treatments for ...